The landscape of new drugs in extranodal NK/T-cell lymphoma

Wang, Liang; Li, Lin-Rong; Zhang, Luo; Wang, Jingwen

doi:10.1016/j.ctrv.2020.102065

Cited by 23 publications

(19 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive and Epstein-Bar virus (EBV)-associated hematologic malignancy, most prevalent in the Far East and South America [1]. No standard treatment strategy has been defined.…”

Section: Dear Editormentioning

confidence: 99%

Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals

Yang

Liu

et al. 2020

APT

Self Cite

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 99%

Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals

Yang

Liu

et al. 2020

APT

Self Cite

View full text Add to dashboard Cite

“…2 Immunotherapeutic agents, such as daratumumab, an anti-CD38, have demonstrated efficacy in EKTL. [26][27][28] This monoclonal antibody works via antibody-dependent cellular phagocytosis and antibody-dependent cellmediated cytotoxicity. 27 Our patient received daratumumab given high tumor expression on his tissue but unfortunately died of his cancer shortly after.…”

Section: Discussionmentioning

confidence: 99%

Extranodal NK/T-Cell Lymphoma, Nasal Type: A Case Series

Marks¹,

Ghandour²,

Collins³

et al. 2022

J Cancer Treatment Diagn

View full text Add to dashboard Cite

Extranodal Natural Killer/T-cell lymphoma, Nasal Type is a rare and aggressive Non-Hodgkins Lymphoma associated with the Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis. We describe three patient presentations at two medical centers in New Orleans, Louisiana, observed within a six-month interval. Although the disease has a lower incidence in the US than in Asia and Latin America, the incidence appears to be on the rise. Due to the spectrum of clinical presentations and low index of suspicion for the disease, presenting signs and symptoms of ENKL may be misattributed to a non-neoplastic condition, resulting in a delay in diagnosis. Increased awareness of the clinical and pathologic spectrum of ENKL, particularly in non-endemic areas, remains an essential means of preventing delay in diagnosis and early initiation of treatment.

show abstract

“…The complete remission rates ranged from 30% to 50% with these regimens. [13] Refractory disease and relapse are common, the outcome and survival rates of which remain poor irrespective of therapy with reported median progressionfree survival of 8 months or less. [14] A study from China reported a 2-year survival rate of 33.3.%.…”

Section: Discussionmentioning

confidence: 99%

Unusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemma

Kilaru

Panda

Mishra³

et al. 2021

IJMIO

View full text Add to dashboard Cite

Extra-nodal Natural killer/T cell lymphoma (ENKTL) is a well-defined and highly aggressive form of NonHodgkin’s lymphoma with a scarcity of cases reported in literature. The most common primary site of involvement is the nasal cavity followed by skin and the gastrointestinal tract (GIT). Cutaneous involvement is a rarity. More than 95% of cases are usually in association with Epstein Barr Virus (EBV) infection. EBV negative ENKTL can be similar in clinical, pathological, and prognostic characteristics with EBV positive ENKTL. This malignancy is usually characterized by its poor prognosis irrespective of clinical stage and therapy. We describe here, a 58-year-old man presenting with multiple nodular lesions over legs and trunk, had an ileal perforation later, and was diagnosed as ENKTL on the ileal biopsy specimen. This case is being reported in view of the fulminant clinical course of the disease, simultaneous involvement of the GIT and skin without nasal or midline involvement, the usefulness of immunohistochemistry in arriving at a diagnosis, and EBV negativity which is quite rare in the Asian population.

show abstract

The landscape of new drugs in extranodal NK/T-cell lymphoma

Cited by 23 publications

References 96 publications

Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals

Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals

Extranodal NK/T-Cell Lymphoma, Nasal Type: A Case Series

Unusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemma

Contact Info

Product

Resources

About